Combined modality approach to treatment of XXXX --re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.

@entity1 @entity137 @entity2699 @entity11 @entity3600 @entity816 @entity463
The Radiation Therapy Oncology Group (RTOG) and the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial in @entity1 with @entity11 to evaluate 4 treatment arms: 1) 60 Gy to the whole brain; 2) 60 Gy plus 10-Gy boost; 3) 60 Gy plus @entity3600 (BCNU); and 4) 60 Gy plus semustine plus @entity2699 . Between September 1974 and March 1979, 626 @entity1 with @entity11 were treated on protocol RTOG 7401/ECOG 1374. Each institution chose a subset of the treatments to which the @entity1 would be randomized. @entity1 were stratified according to subset and randomized to the 4 treatment arms. There were no differences in survival among treatment arms. For @entity1 greater than 60 years of age, the addition of chemotherapy to radiation therapy did not improve survival. For @entity1 aged 40-60 years, there was a statistically significant increase in overall survival when BCNU was added to 60 Gy (P less than .01), with an increase in 2-year survival from 8% to 23%. This beneficial effect of BCNU is apparent in both histological groups ( @entity816 with atypical or anaplastic foci and @entity463 multiforme). Although few confirmatory autopsies are available, long-term survival in @entity1 with @entity816 with atypical and anaplastic foci who were treated with 60 Gy plus BCNU (5-yr survival, 22%) suggests no significant late CNS @entity137 , compared to 60 Gy alone (5-yr survival, 15%). This is confirmed by comparable neurological function in long-term survivors.
